Shaping the future of small molecule drug discovery
Jubilant Biosys Limited, a leading partner in small molecule drug discovery, with drug hunting expertise in Oncology, Metabolic Disorders, Central Nervous System (CNS) diseases, Pain & Inflammation and Rare Diseases. Over the last two decades, it has emerged as an integrated CRDMO service provider with 3 R&D centers, Noida, Greater Noida and Bengaluru, along with a manufacturing plant in Nanjangud, India with a multi-tonne capacity.
With a track-record of 85+ successful Integrated Drug Discovery programs, Biosys has also delivered a noteworthy, Pre-clinical candidate in 18 months.
Jubilant Biosys is a subsidiary of the Jubilant Pharmova family, a flagship of the Jubilant Bhartia Group, has a global workforce of around 46,000 employees, a strong presence in diverse sectors like Pharmaceuticals, Life Science Ingredients, Contract Research & Development Services and Therapeutics, Performance Polymers, Food Service (QSR), Food, Auto, Consulting in Aerospace and Oilfield Services. The team delivers value to customers in over 100 countries and is recognized as a ‘Partner of Choice’ by leading pharmaceuticals and life sciences companies worldwide.
Fostering the Future of Discovery Chemistry
The state-of-the-art Chemistry Innovation Research Center (CIRC), Greater Noida was inaugurated in 2021, and is a steadfast example of investments in infrastructure, modern technology, processes and most importantly, the people, scientists, who will play a key role in driving Discovery Chemistry, rapid & reliable in-vitro ADME expertise, at this site. The facility houses more than 500 scientists, and is designed to fast-track collaboration - ranging from 10 to 200+ FTEs – with dedicated laboratories
- 200,000 sq. ft. of modular lab space
- 8 - 200+ FTE projects - Dedicated labs, Floor, or whole block
- Housing 500+ FTE’s at one site
- Higher instrument ratios per FTE on each floor for LC-MS, HPLC
- NextGen Digital Fume-hoods (US & EU compliant) with webcams, temp. & proximity sensors
- 50% solar powered facility
- IP security and remote monitoring
- COVID-19 measures built into design for safety
Integrated ADME Support
Over the last two decades, we have demonstrated how we can accelerate Drug Discovery pipelines by coupling Discovery Chemistry, rapid and reliable in-vitro ADME studies, under one roof. That is why our latest Chemistry Innovation Research Center (CIRC), Greater Noida, hosts a dedicated DMPK team that enables unparalleled efficiency for discovery programs, across multiple therapeutic areas.
Fostering Integrated Drug Discovery
The Integrated Drug Discovery Center in Bengaluru, has delivered over 85+ integrated drug discovery and many clinical candidates, over the years. Multi-disciplinary, cross-functional expertise coupled with global scientific leadership delivers successful drug discovery projects from Target Identification to Candidate Selection and further, drug substance manufacturing from late pre-clinical to commercial supplies.
Accelerating Drug Discovery Projects for Seed Stage/Small Biotech’s to serving the global top 10 Pharma, the scientific team has a curated approach to fast-tracking pipelines with varied modalities and custom requirements. Exhaustive testing of compounds is key to Integrated Drug Discovery.
About Jubilant Pharmova
Jubilant Pharmova Ltd is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.
The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of over 50 radiopharmacies in the US.
About Drug Discovery Innovation Programme 2022
Drug Discovery Innovation Programme is an invitation-only and one of the best platforms to learn the latest insights and develop lasting business relationships.
This year’s Drug Discovery Innovation Programme will highlight the challenges discovery pipelines have faced due to COVID-19 and will put a spotlight on thec adoption of technology to finding the solutions.
With over 100+ attendees, learn how modernization in R&D processes is fundamentally changing what the drug discovery research will look like in the next two to five years.
So, join us in 2022 for an in-person experience and 2-days of top-level strategic content and the current scientific insights, networking, and discussions from leading global pharmaceutical R&D executives.
Companies in attendance for 2022 will include Servier Pharmaceuticals, Monte Rosa Therapeutics, University of Oxford, WPD Pharmaceuticals, AISA Therapeutics, Anima Biotech, PDC*line Pharma, Eli Lillly and Company, Symphogen, IRB Barcelona, Axonis Therapeutics, Genentech, Arakis Therapeutics, Johnson & Johnson, Amgen, Revitale Pharma, Progenra Inc, CERo Therapeutics, Merck and much more.